Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caldaret is a small molecule investigational drug that acts as an intracardiac calcium (Ca2+) handling modulator. Its presumed cardioprotective mechanism involves inhibition of the sodium/calcium exchanger 1 (NCX1), particularly the reverse-mode Na+/Ca2+ exchange, and enhancement of Ca2+ uptake via the sarcoplasmic reticulum. Caldaret was developed for potential use in cardiovascular diseases, especially to limit infarct size and protect cardiac tissue during ischemia-reperfusion injury such as acute myocardial infarction. Despite promising preclinical results, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention in patients with acute myocardial infarction[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caldaret.